These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34145696)

  • 1. Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study.
    Sadetsky N; Chuo CY; Davidoff AJ
    Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1233-1241. PubMed ID: 34145696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
    Drakaki A; Dhillon PK; Wakelee H; Chui SY; Shim J; Kent M; Degaonkar V; Hoang T; McNally V; Luhn P; Gutzmer R
    Oncoimmunology; 2020 Oct; 9(1):1824645. PubMed ID: 33101774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
    Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
    Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
    Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
    Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
    Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
    Felip E; Ardizzoni A; Ciuleanu T; Cobo M; Laktionov K; Szilasi M; Califano R; Carcereny E; Griffiths R; Paz-Ares L; Duchnowska R; Garcia MA; Isla D; Jassem J; Appel W; Milanowski J; Van Meerbeeck JP; Wolf J; Li A; Acevedo A; Popat S
    Eur J Cancer; 2020 Mar; 127():160-172. PubMed ID: 32028209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
    Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
    J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
    Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
    Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
    Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
    Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
    Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer.
    Hess LM; Smith D; Cui ZL; Montejano L; Liepa AM; Schelman W; Bowman L
    J Drug Assess; 2020 Dec; 10(1):10-17. PubMed ID: 33403155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
    Yang M; MacEwan JP; Boppudi SS; McClain MR; O'Hara RM; Paik PK
    Cancer Med; 2023 Dec; 12(24):21605-21614. PubMed ID: 38062905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility and safety of maintenance chemotherapy in advanced non-small cell lung cancer across various performance status categories: real-world experience.
    Prasad KT; Muthu V; Biswas B; Malik PS; Dabkara D; Ganguly S; Ghosh J; Kataria B; Khurana S; Verma S; Singh N
    Curr Probl Cancer; 2020 Jun; 44(3):100565. PubMed ID: 32173058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.
    Xue Y; Zheng K; Xue J
    Ann Palliat Med; 2021 Sep; 10(9):10114-10123. PubMed ID: 34628932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada.
    Dawe DE; Rittberg R; Syed I; Shanahan MK; Moldaver D; Bucher O; Galloway K; Reynolds K; Paul JT; Harlos C; Kim JO; Banerji S
    Front Oncol; 2023; 13():1191920. PubMed ID: 38125937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
    Käsmann L; Taugner J; Eze C; Roengvoraphoj O; Dantes M; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
    Anticancer Res; 2019 Sep; 39(9):5077-5081. PubMed ID: 31519618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population.
    Jiménez Galán R; Prado-Mel E; Pérez-Moreno MA; Caballano-Infantes E; Flores Moreno S
    Biology (Basel); 2021 Sep; 10(9):. PubMed ID: 34571767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
    Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.